21.79
+6.71%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Assembly Biosciences
From its filings with the US Securities and Exchange Commission
Assembly Biosciences is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ASMB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $72.3m and a net loss of $6.1m. At that date it held total assets of $257.6m and shareholders' equity of $206.8m.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Dec 2010
- Employees
- 73
- Website
- assemblybio.com ↗
- Head office
- TWO TOWER PLACE, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. William RingoNon-Executive Independent Chairman of the Board$139,251
- Mr. Jason OkazakiPresident, Principal Executive Officer, Director, since 2020$1.8m
- Ms. Jeanette BjorkquistPrincipal Financial Officer, Principal Accounting Officer
- Dr. William DelaneyChief Scientific Officer$963,467
- Dr. Anuj GaggarChief Medical Officer
- Dr. Nicole WhiteChief Manufacturing Officer$827,537
- Dr. Tomas CihlarDirector
- Mr. Robert CookDirector
- Dr. John MchutchisonDirector, since 2019$81,751
- Mr. Anthony AltigIndependent Director$96,751
- Ms. Gina ConsylmanIndependent Director$89,251
- Sir Michael HoughtonIndependent Director$76,751
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 77
- Environment
- 53
- Social
- 99
- Governance
- 78
- Women in the workforce
- 47%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Assembly Biosciences develops innovative HBV therapeutics targeting core protein Allosteric Modulators for chronic hepatitis B virus treatment.
- The company's Microbiome Program includes GEMICEL for targeted oral delivery to the lower GI tract.
- Assembly Biosciences has two platform programs focused on infectious disease solutions with 73 employees.
Weaknesses
- The company employs only 73 full-time employees, which may limit research capacity.
- Assembly Biosciences has no products approved for market, relying on development stages.
- The firm's business is concentrated on two platform programs without diversified revenue streams.
Opportunities
- The global hepatitis B market offers significant growth potential for Assembly Biosciences' HBV therapeutics.
- The Microbiome Program could expand into new therapeutic areas beyond dysbiotic microbiome illnesses.
- Increasing focus on infectious disease treatments presents opportunities for Assembly Biosciences' platform programs.
Threats
- The biotechnology sector faces intense competition from larger pharmaceutical companies with more resources.
- Regulatory hurdles may delay approval of Assembly Biosciences' HBV and microbiome therapies.
- Economic downturns could impact funding for biotech research and development projects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.